# A Single Dose Study to Investigate the Pharmacokinetics of MK-0941 in Participants With Renal Insufficiency (MK-0941-015-02)

> **NCT00830791** · PHASE1 · TERMINATED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 32 (actual)

## Conditions studied

- Type 2 Diabetes

## Interventions

- **DRUG:** MK-0941 20 mg
- **DRUG:** MK-0941 5 mg

## Key facts

- **NCT ID:** NCT00830791
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2009-01
- **Primary completion:** 2009-09
- **Final completion:** 2009-09
- **Target enrollment:** 32 (ACTUAL)
- **Last updated:** 2015-02-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00830791

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00830791, "A Single Dose Study to Investigate the Pharmacokinetics of MK-0941 in Participants With Renal Insufficiency (MK-0941-015-02)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00830791. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*